HCA vs. GSK, GILD, REGN, MCK, BMY, ZTS, BSX, BDX, CI, and VRTX
Should you be buying HCA Healthcare stock or one of its competitors? The main competitors of HCA Healthcare include GSK (GSK), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), McKesson (MCK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), The Cigna Group (CI), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
HCA Healthcare (NYSE:HCA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
GSK has a net margin of 16.24% compared to HCA Healthcare's net margin of 8.07%. HCA Healthcare's return on equity of 996.30% beat GSK's return on equity.
62.7% of HCA Healthcare shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 1.6% of HCA Healthcare shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
GSK has lower revenue, but higher earnings than HCA Healthcare. GSK is trading at a lower price-to-earnings ratio than HCA Healthcare, indicating that it is currently the more affordable of the two stocks.
In the previous week, HCA Healthcare had 21 more articles in the media than GSK. MarketBeat recorded 35 mentions for HCA Healthcare and 14 mentions for GSK. HCA Healthcare's average media sentiment score of 0.60 beat GSK's score of 0.23 indicating that HCA Healthcare is being referred to more favorably in the media.
HCA Healthcare received 380 more outperform votes than GSK when rated by MarketBeat users. Likewise, 77.22% of users gave HCA Healthcare an outperform vote while only 57.04% of users gave GSK an outperform vote.
HCA Healthcare currently has a consensus target price of $310.88, indicating a potential upside of 1.39%. Given HCA Healthcare's stronger consensus rating and higher probable upside, research analysts clearly believe HCA Healthcare is more favorable than GSK.
HCA Healthcare pays an annual dividend of $2.64 per share and has a dividend yield of 0.9%. GSK pays an annual dividend of $1.59 per share and has a dividend yield of 3.9%. HCA Healthcare pays out 13.9% of its earnings in the form of a dividend. GSK pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
HCA Healthcare has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Summary
HCA Healthcare beats GSK on 14 of the 20 factors compared between the two stocks.
Get HCA Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCA Healthcare Competitors List
Related Companies and Tools
